Dr. Shaw, let's talk about what happened on the medical side since the last time we spoke.

spoke.Great. Um, thanks for having me.

So definitely, uh, I believe some people are aware of the new breakthrough drug that was FDA approved this summer, deruxinumab, which is a targeted therapy against a KRAS, um, protein.

This KRAS protein is considered...

It's a, it's a gene, I guess, that causes, um...

It's called an oncogene.

So when there's a mutation in this gene, it turns on, uh, I guess the ability for that cell to proliferate, to not sort of, you know, die as it should, as it normally should, and that's essentially what causes cancer.

Dr. Shah, how does this treatment work in comparison to, um, treatments that patients have traditionally had in the past?